Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This randomised, controlled, multicentre trial is designed to assess the efficacy and safety of sequential icotinib plus chemotherapy versus single icotinib as first-line treatment in stage IIIB/IV lung adenocarcinoma patients with EGFR mutation.
Epistemonikos ID: ca1aa7bfa2d1636a7a75008ea96aba9ad52120e9
First added on: May 11, 2024